



**LIVINGSTONE HEALTH HOLDINGS LIMITED**  
(Formerly known as Citicode Ltd.)  
(Incorporated in the Republic of Singapore)  
(Company Registration Number 200404283C)

---

**ISSUANCE AND ALLOTMENT OF DEFERRED CONSIDERATION SHARES**

---

*Unless otherwise defined, all capitalised terms used in this announcement shall have the meanings ascribed to them in the Company's announcement dated 20 May 2022 (the "**Previous Announcement**") and the circular dated 31 December 2020 ("**Circular**").*

The board of directors (the "**Board**" or "**Directors**") of Livingstone Health Holdings Limited (the "**Company**") and together with its subsidiaries, the "**Group**") refers to the Previous Announcement and the Circular.

**Introduction**

The Company had on 31 December 2020 obtained the listing and quotation notice ("**LQN**") from the SGX-ST for, *inter alia*, the listing and quotation of up to 342,500,000 Consideration Shares, which included up to 117,500,000 Deferred Consideration Shares.

**Issuance and Allotment of Deferred Consideration Shares**

The Board is pleased to announce that pursuant to the SPA, and as referenced in the Previous Announcement, an aggregate of 117,500,000 Deferred Consideration Shares has been allotted and issued to the Vendors and Assignees today, on 1 June 2022.

The Deferred Consideration Shares are expected to be listed and quoted on the Catalist Board of the SGX-ST on 2 June 2022 and trading of the Deferred Consideration Shares is expected to commence from 9.00 a.m. on the same date. The approval in-principle granted by SGX-ST for the listing and quotation of the Deferred Consideration Shares is not to be taken as an indication of the merits of the Deferred Consideration Shares, the Company, its subsidiaries and their securities.

By Order of the Board  
**Livingstone Health Holdings Limited**

Dr Tay Ching Yit, Wilson  
Chief Executive Officer

1 June 2022

---

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms. Tay Sim Yee at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, Telephone (65) 6232 3210.*